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Abstract
Background: Nerve damage in leprosy often causes disabilities and deformities. Prednisolone is used to treat nerve
function impairment (NFI). However, optimal dose and duration of prednisolone treatment has not been
established yet. Besides treating existing NFI it would be desirable to prevent NFI. Studies show that before NFI is
clinically detectable, nerves often show subclinical damage. Within the ‘Treatment of Early Neuropathy in LEProsy’
(TENLEP) study two double blind randomized controlled trials (RCT) will be carried out: a trial to establish whether
prednisolone treatment of 32 weeks duration is more effective than 20 weeks in restoring nerve function in leprosy
patients with clinical NFI (Clinical trial) and a trial to determine whether prednisolone treatment of early sub-clinical
NFI can prevent clinical NFI (Subclinical trial).
Methods: Two RCTs with a follow up of 18 months will be conducted in six centers in Asia. In the Clinical trial
leprosy patients with recent (< 6 months) clinical NFI, as determined by Monofilament Test and Voluntary Muscle
Test, are included. The primary outcomes are the proportion of patients with restored or improved nerve function.
In the Subclinical trial leprosy patients with subclinical neuropathy, as determined by Nerve Conduction Studies
(NCS) and/or Warm Detection Threshold (WDT), and without any clinical signs of NFI are randomly allocated to a
placebo group or treatment group receiving 20 weeks prednisolone. The primary outcome is the proportion of
patients developing clinical NFI. Reliability and normative studies are carried out before the start of the trial.
Discussion: This study is the first RCT testing a prednisolone regimen with a duration longer than 24 weeks. Also it
is the first RCT assessing the effect of prednisolone in the prevention of clinical NFI in patients with established
subclinical neuropathy. The TENLEP study will add to the current understanding of neuropathy due to leprosy and
provide insight in the effectiveness of prednisolone on the prevention and recovery of NFI in leprosy patients. In
this paper we present the research protocols for both Clinical and Subclinical trials and discuss the possible findings
and implications.
Trial registration: Netherlands Trial Register: NTR2300
Clinical Trial Registry India: CTRI/2011/09/002022
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Background
Damage to peripheral nerves is the main consequence of
leprosy and may cause deformities and disabilities in
patients. Nerve damage can occur before, during and
after multidrug therapy (MDT) and is a result of inflam-
mation in the nerves due to immunological reactions
[1]. For many years corticosteroids, mostly prednisolone,
have been used to treat nerve function impairment
(NFI) in leprosy patients [2]. However, an optimal dose
and duration of steroid treatment has yet to be estab-
lished [3]. In addition, research should focus also on
possibilities of timely detection and treatment of early
(subclinical) neuropathy in order to prevent NFI and its
consequences [4]. The TENLEP study is designed to ob-
tain additional information about prednisolone treat-
ment for preventing and restoring nerve function in
people affected by leprosy. Within the TENLEP
study two randomized clinical trials will be conducted;
one trial focusing on patients with subclinical neur-
opathy, and the second trial focusing on patients with
clinical NFI.
Between 6 and 27% of the 228 474 newly detected lep-
rosy cases in 2010 [5] presented with visible impairment
(grade 2 disability) [2,4]. This WHO leprosy disability
grading system is the most widely used method to assess
impairment in leprosy patients and is generally used for
monitoring program quality [6,7]. More accurate assess-
ments for NFI are Voluntary Muscle Testing (VMT) and
Monofilament Testing (MFT) or ball point tests [8],
which are widely used in clinical practice to assess motor
and sensory NFI, respectively. Recently, more sensitive
methods have been introduced to detect early, subclin-
ical neuropathy. The INFIR study found that nerve con-
duction studies (NCS) and Warm Detection Threshold
(WDT) are the most effective methods for finding
subclinical nerve damage [1]. With these tests subclinical
neuropathy can be detected at least 3 months before VMT
and MFT can determine the first clinical impairments.
Sub-clinical changes during and following MDT were also
found to be predictive of new onset NFI [9].
To examine treatment of clinical NFI several studies
have been conducted using prednisolone. In one cohort
the WHO recommended prednisolone regimen (starting
with 40 mg prednisolone/day, tapered down over
12 weeks [2]) was found not to be successful in the pre-
vention and reversal of NFI in multibacillary (MB)
patients treated for reactions or neuropathy [10]. Also a
16-week prednisolone regimen, usual practice nowadays,
was found not to be very effective in two randomized
controlled trials (RCT) [11,12]. One trial was in patients
with Type 1 Reactions and/or NFI, receiving either pred-
nisolone or prednisolone with intravenous methylpred-
nisolone. Close to 50% of the patients required
additional prednisolone during or after the treatment
period [11]. The second RCT in MB patients with mild
sensory impairment did not show a difference in NFI as
measured with MFT 12 months after start of prednisol-
one treatment [12]. Van Veen et al. [3], reviewing RCTs
comparing placebo to prednisolone treatment, conclude
that studies so far have not provided enough evidence to
draw robust conclusions about the long-term effect of
corticosteroids on reactions and NFI. However, there is
reason to assume that longer steroid treatment might be
more beneficial, since one study showed that a 5 month
corticosteroid regimen was significantly more effective
than a 3 month regimen [13]. In TENLEP we aim to as-
sess whether prednisolone treatment of 32 weeks dur-
ation is more effective than treatment of 20 weeks
duration in restoring nerve function in patients with
clinical sensory and/or motor NFI of recent onset
(<6 mo), as detected by VMT and/or MFT.
The effect of prednisolone treatment on patients with
subclinical neuropathy to prevent clinical NFI as deter-
mined with MFT and/or VMT has not been studied in a
RCT before. The objective of the Subclinical trial is
therefore to determine whether prednisolone treatment
of early subclinical neuropathy, as detected with WDT
and NCS, would prevent clinical sensory and/or motor
function loss in leprosy patients. This paper presents the
protocols for both the Clinical and the Subclinical trial.
Methods
Definitions
General
Neuropathy (peripheral) Functional impairment and/or
structural damage to autonomic, sensory, and motor
nerve fibers within the peripheral nervous system.
Nerve function impairment Sensory, motor or auto-
nomic neuropathy evidenced by clinically detectable re-
duction in function in sensory, motor and/or autonomic
fibers. The ‘level’ of impairment that is clinically detect-
able depends on the sensitivity of the testing instruments
used. (It does not include abnormality of nerve conduc-
tion that is detectable only by electrophysiological means
and WDT).
Nerve damage An imprecise but common term for
‘neuropathy’, which is also used in relation to trauma.
Here it indicates clinical or subclinical damage to a
nerve, whether reversible or irreversible.
Neuritis A condition in which inflammatory cells are
found in the nerve, detectable by swelling and/or func-
tional impairment with spontaneous nerve pain and/or
nerve tenderness on palpation.
Wagenaar et al. BMC Neurology 2012, 12:159 Page 2 of 9
http://www.biomedcentral.com/1471-2377/12/159
Subclinical neuropathy Patients have normal values for
Voluntary Muscle Testing and Monofilament Testing,
but are impaired on Nerve Conduction Studies (NCS)
and/or Warm Detection Threshold (WDT).
Entry criteria Clinical trial
At least one nerve with either a VMT score of 4 or less
on the 0–5 (modified) MRC scale or with an monofila-
ment threshold increased compared to normal subjects
by three or more monofilament levels on any test-site,
two levels on one test-site AND at least one level on an-
other test-site, OR one level on three or more test-sites
for one nerve. With VMT each nerve is tested with one
specific test assessing the strength of a muscle (group)
innervated by that nerve. For MFT each nerve is tested
on three sites).
Entry criteria Subclinical trial
Any one parameter (Motor Nerve Conduction, Sen-
sory Nerve Conduction, Warm Detection Threshold)
abnormal in at least two nerves or any two parameters
abnormal in at least one nerve. VMT and MFT values
are normal.
Outcome criteria Clinical trial
Restored nerve function
Monofilament Test and/or Voluntary Muscle Test
of a nerve are recovered to normal levels (MFT = 0,
VMT = 5).
Improved nerve function
At least one nerve shows better results on Monofilament
Test and/or Voluntary Muscle Test. The MF thresholds
should be reduced by three or more monofilament levels
on any site, two levels on one site AND at least one level
on another site, OR one level on three or more sites
for one nerve. VMT score should be increased by at least
1 point.
Improved Reaction Severity Scale score
When the score on the Reaction Severity Scale [14]
decreases by at least 3 points on the sum score or at
least 2 points on any individual item in the scale.
Count of nerve function impairments (CNFI)
The sum of MFT and VMT scores (5 being normal) for
all nerves tested in the study.
Improved SALSA score
The SALSA scale [15] score decreases at least with 1
category in standardized categories of SALSA values as
described in SALSA Scale Users Manual (Salsa Scale
Users Manual, Version 1.1, July 2010)
Improved participation scale score
The Participation scale [16] score decreases at least 1
grade on the “Grades of participation restriction” scale
(as described on P-scale form).
Outcome criteria subclinical trial
Clinical motor impairment (MI)
Motor neuropathy resulting in weakness of the muscles
innervated by a given nerve. A patient is diagnosed as
having clinical motor impairment if the VMT score for a
muscle test is 4 or less on the 0–5 (modified) MRC
scale. If a score of 4 is found, the test will be repeated by
a second assessor.
Clinical sensory impairment (SI)
A patient is diagnosed as having sensory impairment of
a nerve if the monofilament threshold is increased by
three or more monofilament levels on any site, two
levels on one site AND at least one level on another site,
OR one level on three or more sites for one nerve.
Subclinical nerve function score (SNFS)
The SubClinical Nerve Function Score (SNFS) will be
computed for NC parameters (amplitude and latency)
and warm detection threshold, where non-impaired par-
ameter adds 1 point to the overall score.
Improved SNFS
SubClinical Nerve Function Score increased with at least
1 point
Deteriorated SNFS
SubClinical Nerve Function Score decreased with at
least 1 point
Design of study
The TENLEP study consists of two multi-centre rando-
mized triple blind controlled trials, both with two treat-
ment arms, to study the effectiveness of prednisolone
treatment restoring (Clinical trial) and in preventing
(Subclinical trial) clinical nerve function loss.
Six institutions in four different countries participate
in this study: Nepal (Lalgadh Hospital and Anandaban
Hospital); India (JALMA Institute for Leprosy -Agra and
Foundation for Medical Research-Mumbai); Bangladesh
(Nilphamari Hospital); and Indonesia (Dr. Soetomo
Hospital- Surabaya). Anandaban Hospital and Dr Soe-
tomo Hospital will only take part in the Clinical trial. All
collaborative institutions are referral hospitals specia-
lized in the detection and treatment of leprosy. At each
institution a Principal Investigator (PI) is responsible for
the research at that centre. The overall responsibility lies
with the International Coordinator (dr. E. Post), guided
by an International Steering Committee.
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Participants
In the Clinical trial leprosy patients with clinical NFI will
be randomly allocated to either treatment of standard
duration (20 weeks) or an interventional treatment of
longer duration (32 weeks). Both multibacillary (MB)
and paucibacillary (PB) patients diagnosed with clinical
sensory and/or motor nerve impairment of less than six
months duration are enrolled. For the Subclinical trial
leprosy patients with subclinical neuropathy will be ran-
domly divided into an intervention group and a placebo
group. Newly registered MB and PB patients without
clinical NFI but having subclinical sensory and/or motor
neuropathy at diagnosis, or developing this within their
first three months of MDT treatment, will be eligible for
inclusion in the trial. Patients from the Subclinical trial
developing NFI in the first three months of the trial can
enter the Clinical trial, but only data of patients that
were allocated to the placebo group of the Subclinical
trial will be analyzed.
Inclusion and exclusion criteria
Patients included in the trials should be between 15 and
60 years of age, must give informed consent and should
be free from conditions that may affect the peripheral
nervous system, such as diabetes mellitus, and other ac-
tive underlying diseases for example hypertension, osteo-
porosis and tuberculosis. Included patients receive
deworming treatment with Mebendazol before steroid
treatment starts. In both studies patients will be
followed-up for 18 months. Excluded will be women
pregnant at diagnosis, patients who need steroids for
reasons other than recent NFI and patients with a single
skin lesion on the trunk as the only sign of leprosy.
Randomization and blinding
In both trials patients will be randomly allocated to one
of the two study arms. Randomization tables are pro-
vided by the statistician and drugs are labeled accord-
ingly by the manufacturer. The key is held by the
International Coordinator, Study Manager and PI of
each centre and will be broken after the data analysis is
completed or earlier for patients with adverse events,
and new or worsening NFI.
Sample size calculation
For the Clinical trial a recovery of 60% is presumed for
the standard regimen in the control group [17]. To de-
tect a recovery of 70% in the treatment group, compen-
sating for 20% of loss to follow-up, a total of 720
subjects need to be enrolled.
The INFIR study shows that of the leprosy patients
having subclinical neuropathy 16% will eventually de-
velop clinical NFI [1]. For the Subclinical trial we as-
sume a reduction in patients developing clinical NFI by
half in the treated group (8%). Anticipating a loss to
follow-up of 20% at 18 months, a sample size of 275
subjects per trial arm is required. For both sample size
calculations a one-tailed alternative hypothesis, 80%
power and 5% significance is used.
Follow-up
Patients will be followed-up for 18 months. Nerve func-
tion is monitored by monthly VMT and MFT in both
trials and assessments with NCS and WDT takes place
at 20 weeks, 12 and 18 months from intake in the Sub-
clinical trial. Participants can be withdrawn from the
trials because of medical or clinical reasons or preg-
nancy. Subjects missing their appointment will be visited
at home by research staff within two weeks when con-
tact by cell phone is not possible or did not result in late
attendance at the clinic. In cases when only one appoint-
ment is missed and medication is not taken for a max-
imum of one month, treatment will continue from the
first package missed. The TENLEP trials started in April
2012, with a duration of intake of 1.5 years.
Medication
In both trials the medication provided is prednisolone.
Prednisolone will be allocated based on two bodyweight
classes. The low weight class (patients below 50 kg), will
receive prednisolone treatment based on a body weight
of 45 kg. The high weight class (patients 50 kg and
more) receives treatment based on a body weight of
60 kg.
Treatment arms
In the Clinical trial patients in the treatment arm receive
prednisolone for 32 weeks, in tablets of 5 mg. The con-
trol arm will follow a regimen of 20 weeks and receive
placebo tablets to keep the number of tablets equal to
the treatment group for effective treatment time and
duration. The dose in both intervention and control arm
starts at 1 mg/kg/day (either 45 or 60 mg/day depending
on weight class) and will be tapered down over 32 and
20 weeks, respectively. Figure 1a shows the dose over
time of both arms in the Clinical trial. In contrast to
previous trials, the middle range of the prednisolone
dose will be maintained at a high level (0.44 mg/kg/day)
for a longer period (12 weeks). In the Subclinical trial
patients receive either prednisolone or placebo for
20 weeks in tablets of 5 mg. The prednisolone dose
starts at 1 mg/kg/day (either 45 or 60 mg/day depending
on weight class) and will be tapered down over 20 weeks.
Figure 1b shows the timeline and dosage. The total dos-
age of prednisolone over 20 weeks will be 2.8 grams for
patients under 50 kg body weight, and 3.7 grams for
patients over 50 kg body weight.
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Adverse events
Prednisolone has known adverse events, ranging from
mild adverse events, such as moon face, fungal infec-
tions and acne, to serious adverse events such as peptic
ulcer, osteoporosis glaucoma, cataract, psychosis, dia-
betes and hypertension [18,19]. Serious adverse events
have not been encountered frequently in previous trials
studying prednisolone for treating NFI in leprosy
patients [20], however strict monitoring of adverse
events will take place in the TENLEP trials. In case of
serious adverse effects the PI will break the key and initi-
ate an individualized treatment scheme. In the event of
minor side effects additional medication will be pre-
scribed according to normal protocol in the clinic, but
the key will not be broken.
Data collection
General assessments
Before intake, the general health of all possible eligible
patients will be checked and history will be taken accord-
ing to the protocol. Additionally, patients will be tested
for specific medical conditions related to neuropathy and
prednisolone intake such as diabetes mellitus (urine test)
and osteoporosis (FRAX). Leprosy status will be
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Figure 1 a. Timeline prednisolone dose for patients under 50 kg in the Clinical trial. b. Timeline prednisolone dose for patients under
50 kg in the Subclinical trial.
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categorized using both WHO classification (PB/MB), and
Ridley-Jopling classification [21]. The latter will be done
on clinical grounds, but a skin biopsy can be taken on vol-
untary basis for confirmation of the classification by a
trained pathologist. For this procedure an additional con-
sent procedure is in place. Of each patient a slit skin
smear will be taken for determining the Bacteriological
Index (BI).
Clinical nerve function tests
After intake, eligible subjects will be assessed for clinical
sensory and motor nerve impairment. The clinical sen-
sory function is tested with monofilaments using a
standard set of 5 Semmes-Weinstein monofilaments
ranging from blue (200 mg) to pink (300 g) [22]. This
test of touch sensibility is based on indenting the skin
surface with a series of standard nylon filaments. For
each thickness it is recorded whether or not the patient
feels the touch, starting with the thinnest filament. For
hands the normal threshold is the blue filament and for
feet the purple (2 mg) filament; when these filaments are
felt by the patient it results in a score of 0. The score
increases with 1 for each thicker filament not felt, with a
maximum score of 5 in hands and 4 in feet (filament of
300 g not felt) for every site. Each nerve will be tested
on 3 sites. The trigeminal nerve is tested by assessing
the blink regularity. A patient is diagnosed as having
sensory impairment if the monofilament threshold is
increased by three or more monofilament levels in one
single nerve (over 3 sites).
Motor nerve impairment will be assessed with Vol-
untary Muscle Testing (VMT) using the 0–5 MRC
scale [23,24]. The test is performed by checking the
ability of the patient to move a body part to a given
position and to hold that position against resistance
applied by the tester. A nerve scoring lower than 5 is
considered impaired. When a single score of 4 is
found this score should be independently confirmed by
a second assessor.
Subclinical nerve function tests
When new patients show no abnormal values by VMT
and MFT they will be tested further for possible inclu-
sion in the Subclinical trial. For detecting subclinical
neuropathy sensory and motor Nerve Conduction Stud-
ies (NCS), carried out with the Neurocare 2000W EMG
machine (BioTech Ltd, Mumbai), and Warm Detection
Threshold (WDT) test, using the TSA II (MEDOC, Is-
rael), will be performed. NCS and WDT will take place
in an air-conditioned room at approximately 20-25°C.
All assessments will be carried out at both sides of the
body. Table 1 shows which nerves will be tested and
methods used. MFT and VMT will be assessed at start
of the trial and subsequently every month in both stud-
ies and follow-up periods on all subjects. WDT, Sensory
Nerve Conduction (SNC) and Motor Nerve Conduction
(MNC) will be carried out at baseline, end of treatment
period (20 weeks) and at 12 and 18 months. For the
Clinical trial additional information will be obtained
using the Reaction Severity Scale (RSS) [25], the Screen-
ing of Activity Limitation and Safety Awareness (SALSA)
scale [26] and the Participation Scale [27]. All scales will
be filled in at baseline, end of treatment period
(32 weeks), 12 and 18 months.
Reliability and normative studies
Prior to intake inter-tester reliability studies have taken
place for all assessments (MFT, VMT, WDT, NCS) to
test and improve comparability of the results and ensure
high measurement quality. After reliability studies for
NCS and WDT, normative studies were carried out
to establish the local normal values for each separate
collaborative centre. For each nerve a minimum of
150 normal subjects from surrounding areas were
tested, equally spread over both sexes and 3 age categor-
ies (15–30, 31–45 and 46–60 years of age). Normal
subjects will be screened to ascertain they do not have
diabetes or nerve function impairment.
Standard operating procedures and training
For all assessments standard operating procedures (SOP)
have been developed. To achieve consistency of the
assessments between all research centers, the PI and
two main assessors of each centre received training in
research protocol procedures and handling equipment.
In addition, an online Good Clinical Practice (GCP)
course was completed by all PI’s.
Outcome measures
The Clinical trial
The primary study outcome is the proportion of patients
with restored and improved nerve function (of all
nerves) measured by VMT/MFT at 18 months. Second-
ary outcomes are based on results of the Reaction Sever-
ity Scale, SALSA and Participation Scale (Figure 2).
Table 1 Nerves assessed by the different methods
Nerve VMT MFT MNC SNC WDT
Trigeminal blink
Facial x
Ulnar x x x x x
Median x x x x x
Radial x x x x
Common peroneal x x
Post. Tibial x x x x
Sural x x x
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Furthermore, a Count of Nerve Function Impairment
(CNFI) will be computed to measure the results of treat-
ment on nerve function, with special interest for
most commonly affected nerves. The CNFI will consist
of the count of nerve function impairments detected by
monofilament and VMT testing and will be validated in
this trial.
The Subclinical trial
The proportion of patients developing clinical NFI as
measured by MFT and VMT is the primary outcome in-
dicator (Figure 2). Secondary outcome measures focus
on results of the specific assessments for detection of
subclinical neuropathy (WDT, SNC and MNC).
Data analysis
After the data is entered for each centre, data will be
checked and cleaned. Regular weekly back-ups will be
made for local off-site storage in addition to a monthly
upload of data via a web-based repository to the project
statistician.
Reliability studies
Inter-rater reliability for categorical outcomes of VMT
and MFT are assessed using weighted Kappa statistics.
Comparing differences and averages of paired assess-
ments for WDT, SNC and MNC tests are based on
Bland-Altman plots. In addition, a mixed model analysis
of variance will be used to compute the intraclass correl-
ation coefficient.
Normative studies
To determine normative values for WDT and NCS for
each centre, outliers are excluded before limits of nor-
mal function are calculated using an approach based on
regression analysis taking into account age-related
trends. The 97.5th percentile is used to define abnormal
function.
Primary outcomes
Analysis of primary outcomes will be done at 20 (Sub-
clinical trial) or 32 weeks (Clinical trial), 12 and
18 months. Possible effects of potential covariates (gen-
der, age, leprosy classification) will be assessed with
ANCOVA. All analyses will be carried out using Stata
statistical software.
Secondary outcomes
Continuous outcome measures will be analyzed with
Analysis of (co)variance, assessing one or more covari-
ates. Categorical outcomes may be analyzed using chi-
squared test or log linear models. For Survival outcomes
the log rank test will be used.
Ethics
All national Research Ethics Committees have approved
the study protocol, which are for India: Indian Council
of Medical Research; Nepal: Nepal Health Research
Council (NHRC); Indonesia: Komite Etik Penelitian
Kesehatan RSUD Dr. Soetomo Surabaya; Bangladesh:
Bangladesh Medical Research Council- National Re-
search Ethics Committee. In addition all local Research
Ethics Committees have given their approval as well.
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Figure 2 Overview of intake, assessments and outcomes in the Clinical and Subclinical trial.
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Written consent will be obtained from individual sub-
jects before inclusion and for minors additional consent
from their guardians will be sought.
Discussion
This paper describes the protocols of two randomized
controlled clinical trials within the TENLEP study. In
the Clinical trial the effect of long term prednisolone
treatment on the restoration of clinical NFI will be
investigated. In the Subclinical trial the efficacy of pred-
nisolone in preventing the development of clinical NFI,
in patients with subclinical neuropathy, will be
examined.
The optimal dose and duration of prednisolone for
treating clinical NFI in leprosy has not been established
yet and there is not enough evidence available from ran-
domized controlled clinical trials on the long term effect
of prednisolone treatment [3]. The TENLEP study
addresses this knowledge gap and will extend the
current understanding of prednisolone regimens for the
treatment of clinical NFI by comparing a prednisolone
treatment of 32 weeks and 20 weeks under controlled
circumstances. If a 32 weeks treatment proves to be ef-
fective in restoring or improving clinical NFI in leprosy
patients, new guidelines can be developed which can sig-
nificantly improve patient management in leprosy care
and especially a positive effect on the prevention of dis-
abilities (POD) can be expected.
This study will be the first to evaluate prednisolone
treatment for the prevention of clinical NFI in people
affected by leprosy diagnosed with subclinical neur-
opathy. The results of the preceding TRIPOD trial pro-
vide some insight in possible effects of prednisolone in
preventing new NFI [28]. To prevent new NFI and reac-
tions, leprosy patients with and without pre-existing NFI
at diagnosis (as determined with VMT and MFT)
received a prophylactic low dose of prednisolone
(20 mg/day) for four months, tapered down in the last
month. Although a reduced incidence of new NFI and
reactions was observed at the end of treatment at four
months, this was not sustained at one year. More im-
portant however, the preventive effect of prednisolone at
four months was more than three times higher in
patients with no pre-existing NFI [28]. A second study
that has some similarities with our Subclinical trial is of
that of Capadia et al. [29], who studied the effect of
prednisolone on neuropathy as assessed with NCS. In
their study, neuropathy was divided in mild, moderate
and severe groups, as percentages deviating from nor-
mative values. Their findings suggest that a 12-week
prednisolone course is not effective in preventing or re-
versing nerve damage. However, they found that mildly
affected nerves showed higher improvement rates than
moderately and severely affected nerves (53%, 21% and
14% of the nerves improved respectively).
The better outcomes of prednisolone treatment and
prophylaxis on non-affected and mildly affected nerves
from both studies of TRIPOD and Capadia et al. [29]
show the importance of early treatment of neuropathy in
leprosy patients. With the Subclinical trial we hope to
establish that prednisolone treatment can prevent the
development of clinical NFI and in this way can prevent
disabilities and deformities in newly diagnosed leprosy
patients.
If the prednisolone treatment turns out to be effective
in the prevention of clinical NFI, the implementation of
treatment for patients with evident subclinical neur-
opathy in clinical practice will be complicated. The
methods to detect subclinical neuropathy used in this
study (TSA II and Neurocare 2000) will not be available
in the field, since the devices are expensive and condi-
tions under which the assessments have to take place, a
steady environmental temperature of 20–25°C, are diffi-
cult to realize in tropical climates. Therefore it is im-
portant to search for a cheaper, portable method to
detect subclinical neuropathy that can be easily used in
field clinics.
However, also without a test to determine subclinical
neuropathy the results of this study can be useful to im-
prove treatment guidelines. The current prediction rule
allows to distinguish leprosy patients with a high risk for
developing NFI [30]. However, at the moment, providing
prophylactic prednisolone treatment to this group of
patients is considered unethical, as a significant number
of patients will take prednisolone unnecessarily. With the
information of the TENLEP trials we hope the prediction
rule can be refined, so administering prophylactic pred-
nisolone is acceptable in certain, well defined groups.
In conclusion, the TENLEP study will add to the
current understanding of neuropathy due to leprosy and
will provide better insight into the effectiveness of pred-
nisolone treatment in the prevention and recovery of
nerve function loss in leprosy patients. If this study
shows the effectiveness of prednisolone in the preven-
tion and recovery of NFI it will improve treatment
options and contribute therefore to the prevention of
permanent sensory and/or motor nerve function loss in
people affected by leprosy and hence prevent disabilities
and deformities which will improve the lives of many of
these patients.
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